The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Addressing concerns around side effects in clinical trials
Gail Roboz
June 25, 2024
Know AML conducted a poll among patients with acute myeloid leukemia (AML), and their families and caregivers, revealing a concern regarding potential side effects that may be experienced during participation in a clinical trial. Know AML was pleased to speak with Gail Roboz, physician at Weill Cornell Medicine and Know AML ambassador, to address this concern.
Roboz emphasizes that clinical trials can offer improved treatment options beyond the standard of care and reassures patients that they often do not involve completely novel drugs. She encourages patients to compare listed side effects in trial treatments to those of standard of care treatments, and to consider participation in clinical trials to potentially benefit from receiving the investigational drug and to contribute to advancing treatment options.
